Yahoo Finance

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

SAN FRANCISCO and BOSTON, Sept. 17, 2025 /PRNewswire/ -- MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an ...
Pharmabiz

MapLight Therapeutics initiates phase 2 ZEPHYR study of M1/M4 muscarinic agonist ML-007C-MA to treat schizophrenia

MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating CNS disorders, announced the initiation of a phase 2 study to ...
Seeking Alpha

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML ...
Pharmabiz

MapLight Therapeutics initiates phase 2 trial of novel M1/M4 muscarinic agonist ML-007C-MA to treat Alzheimer’s disease psychosis

MapLight Therapeutics, a clinical-stage biopharmaceutical company, announced the initiation of a phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel ...